Vanda Pharmaceuticals (VNDA) Accounts Payables (2010 - 2026)

Vanda Pharmaceuticals has disclosed Accounts Payables across 17 years of filings, most recently posting $60.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $60.6 million, up 33.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.6 million (up 33.88% YoY), and the FY2025 annual result was $68.3 million, up 74.74% from the prior year.
• Accounts Payables came in at $60.6 million for Q1 2026 at Vanda Pharmaceuticals, down from $68.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $68.3 million in Q4 2025 to a low of $31.9 million in Q2 2023.
• The 5-year median for Accounts Payables is $45.3 million (2025), against an average of $45.3 million.
• Across the five-year window, Accounts Payables jumped 96.87% in 2022 and tumbled 36.44% in 2023, its largest moves.
• Vanda Pharmaceuticals' Accounts Payables stood at $45.6 million in 2022, then decreased by 15.57% to $38.5 million in 2023, then advanced by 1.63% to $39.1 million in 2024, then jumped by 74.74% to $68.3 million in 2025, then declined by 11.24% to $60.6 million in 2026.
• The last three Accounts Payables figures came in at $60.6 million (Q1 2026), $68.3 million (Q4 2025), and $47.6 million (Q3 2025), per Business Quant data.